Toxpia 100U is an advanced botulinum toxin type A injection developed by HJ Corporation in South Korea. It is designed to treat moderate to severe facial wrinkles, including frown lines, forehead wrinkles, and crow’s feet. Toxpia works by temporarily inhibiting muscle activity, smoothing fine lines, and rejuvenating the skin for a more youthful appearance.

A key advantage of Toxpia is its long-lasting results—effects can last up to 4-6 months, with some reports suggesting improvements persisting for up to 9 months depending on the individual. The product is manufactured using a vacuum-drying technique, which enhances its purity and minimizes protein denaturation during dilution, ensuring consistent efficacy. This makes it a reliable choice for both patients and practitioners.

Each vial of Toxpia contains 100 units of botulinum toxin, along with human serum albumin and sodium chloride for stability. Notably, it starts showing visible results within 72 hours post-injection, providing faster onset compared to some other brands. Toxpia’s production method also ensures precise dosage and ease of administration, contributing to safer outcomes in aesthetic treatments.

Due to its global recognition and safety profile, Toxpia has become a preferred option among professionals seeking reliable botulinum toxin formulations for cosmetic purposes. For optimal storage, it should be kept between 2°C to 8°C, maintaining its stability for up to 36 months from the manufacturing date.

Toxpia 100U stands out for its efficiency, ease of use, and strong performance, making it a valuable option for those looking to achieve smoother, wrinkle-free skin.